{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:27:15Z","timestamp":1784636835504,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-024-07664-2","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T15:02:31Z","timestamp":1722438151000},"page":"2273-2277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Awareness and barriers of sacral neuromodulation in women with overactive bladder"],"prefix":"10.1007","volume":"310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-5395","authenticated-orcid":false,"given":"Christl","family":"Reisenauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Andress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"7664_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/2090598X.2019.1589930","volume":"17","author":"AS El-Azab","year":"2019","unstructured":"El-Azab AS, Siegel SW (2019) Sacral neuromodulation for female pelvic floor disorders. Arab J Urol 17:14\u201322","journal-title":"Arab J Urol"},{"key":"7664_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"7664_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.juro.2017.09.102","volume":"199","author":"D Moskowitz","year":"2018","unstructured":"Moskowitz D, Adelstein SA, Lucioni A et al (2018) Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers-are we doing enough? J Urol 199:779\u2013784","journal-title":"J Urol"},{"key":"7664_CR4","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00192-013-2067-1","volume":"24","author":"F Lugo Salcedo","year":"2013","unstructured":"Lugo Salcedo F, Sanchez Borrego R (2013) Assessment of female prevalence of overactive bladder (OAB) in Barcelona using a self-administered screening questionnaire: the Cuestionario de Autoevaluaci\u00f3n del Control de la Vejiga (CACV). Int Urogynecol J 24:1559\u20131566","journal-title":"Int Urogynecol J"},{"key":"7664_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4321\/S0004-06142007000100003","volume":"60","author":"MJ Garcia Matres","year":"2007","unstructured":"Garcia Matres MJ, Brenes Bermudez FJ (2007) Diagnosis and management of patients with overactive bladder syndrome in urology clinics and general practitioner clinics in Spain. Arch Esp Urol 60:15\u201321","journal-title":"Arch Esp Urol"},{"key":"7664_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5213\/inj.1630382.191","volume":"20","author":"O \u00dc\u00e7er","year":"2016","unstructured":"\u00dc\u00e7er O, Demir \u00d6, Zeren MF, Aegean Study Group of Society of Urological Surgery et al (2016) Assessment of proportion of hidden patients having symptoms of overactive bladder and why has it been hidden in female outpatients admitted to hospital. Int Neurourol J 20:47\u201352","journal-title":"Int Neurourol J"},{"key":"7664_CR7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760\u2013766","journal-title":"BJU Int"},{"key":"7664_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.eururo.2008.01.027","volume":"53","author":"DE Irwin","year":"2008","unstructured":"Irwin DE, Milsom I, Kopp Z, EPIC Study Group et al (2008) Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 53:1029\u20131037","journal-title":"Eur Urol"},{"key":"7664_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00192-016-3195-1","volume":"28","author":"HW Brown","year":"2017","unstructured":"Brown HW, Rogers RG, Wise ME (2017) Barriers to seeking care for accidental bowel leakage: a qualitative study. Int Urogynecol J 28:543\u2013551","journal-title":"Int Urogynecol J"},{"key":"7664_CR10","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00345-023-04447-3","volume":"41","author":"T H\u00fcsch","year":"2023","unstructured":"H\u00fcsch T, Ober S, Haferkamp A et al (2023) Digital health information on surgical treatment options for overactive bladder is underrepresented. World J Urol 41:1891\u20131896","journal-title":"World J Urol"},{"key":"7664_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/00015458.2020.1794338","volume":"121","author":"L Ghijselings","year":"2021","unstructured":"Ghijselings L, Pauwaert K, Verla W et al (2021) Primary care providers\u2019 knowledge about the therapeutic management of refractory pelvic floor dysfunctions in Flanders, Belgium: a cross-sectional study. Acta Chir Belg 121:386\u2013393","journal-title":"Acta Chir Belg"},{"key":"7664_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","volume":"135","author":"LS Phillips","year":"2001","unstructured":"Phillips LS, Branch WT, Cook CB et al (2001) Clinical inertia. Ann Intern Med 135:825\u2013834","journal-title":"Ann Intern Med"},{"key":"7664_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12875-015-0221-1","volume":"16","author":"I Aujoulat","year":"2015","unstructured":"Aujoulat I, Jacquemin P, Hermans MP et al (2015) Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium. BMC Fam Pract 16:13","journal-title":"BMC Fam Pract"},{"key":"7664_CR14","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/j.1742-1241.2008.01870.x","volume":"10","author":"A Wagg","year":"2008","unstructured":"Wagg A, Cardozo L, Chapple C et al (2008) Overactive Bladder and Continence Guidelines: implementation, inaction or frustration? Int J Clin Pract 10:1588\u20131593","journal-title":"Int J Clin Pract"},{"key":"7664_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/01443610903003167","volume":"29","author":"M Basu","year":"2009","unstructured":"Basu M, Duckett JR, Moran P et al (2009) Clinicians\u2019 views on the NICE guideline on the management of female urinary incontinence. J Obstet Gynaecol 29:529\u2013532","journal-title":"J Obstet Gynaecol"},{"key":"7664_CR16","doi-asserted-by":"publisher","first-page":"E165","DOI":"10.5489\/cuaj.8176","volume":"17","author":"P Gariscsak","year":"2023","unstructured":"Gariscsak P, Gray G, Steele S et al (2023) Urologist-perceived barriers and perspectives on the underuse of sacral neuromodulation for overactive bladder in Canada. Can Urol Assoc J 17:E165\u2013E171","journal-title":"Can Urol Assoc J"},{"key":"7664_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5489\/cuaj.2711","volume":"9","author":"MM Hassouna","year":"2015","unstructured":"Hassouna MM, Sadri H (2015) Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can Urol Assoc J 9:242\u2013247. https:\/\/doi.org\/10.5489\/cuaj.2711","journal-title":"Can Urol Assoc J"},{"key":"7664_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jval.2010.08.006","volume":"14","author":"S Arlandis","year":"2011","unstructured":"Arlandis S, Castro D, Errando C et al (2011) Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin A or continued medical management in refractory overactive bladder. Value Heal 14:219\u2013228. https:\/\/doi.org\/10.1016\/j.jval.2010.08.006","journal-title":"Value Heal"},{"key":"7664_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1464-410X.2010.09905.x","volume":"108","author":"RK Leong","year":"2011","unstructured":"Leong RK, de Wachter SGG, Joore MA et al (2011) Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 108:558\u2013564. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09905.x","journal-title":"BJU Int"},{"key":"7664_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/AOG.0000000000003320","volume":"134","author":"A Davenport","year":"2019","unstructured":"Davenport A, Stark S, Quian A et al (2019) A patient-centered approach to refractory overactive bladder and barriers to third-line therapy. Obstet Gynecol 134:141\u2013148","journal-title":"Obstet Gynecol"},{"key":"7664_CR21","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00192-014-2360-7","volume":"25","author":"P Balchandra","year":"2014","unstructured":"Balchandra P, Rogerson L (2014) Women\u2019s perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J 25:1059\u20131064","journal-title":"Int Urogynecol J"},{"key":"7664_CR22","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s11255-015-1100-3","volume":"47","author":"H Hashim","year":"2015","unstructured":"Hashim H, Beusterien K, Bridges JF et al (2015) Patient preferences for treating refractory overactive bladder in the UK. Int Urol Nephrol 47:1619\u20131627","journal-title":"Int Urol Nephrol"},{"key":"7664_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/nau.25109","volume":"42","author":"J Speed","year":"2023","unstructured":"Speed J, Welk B, Comiter C et al (2023) Determining patient preferences in the treatment of medication-refractory overactive bladder. Neurourol Urodyn 42:419\u2013426","journal-title":"Neurourol Urodyn"},{"key":"7664_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/2051415817742565","volume":"11","author":"R Nobrega","year":"2018","unstructured":"Nobrega R, Greenwell T, Pickard R et al (2018) Sacral nerve stimulation versus intravesical botulinum toxin injections for medically refractory overactive bladder: a contemporary review of UK treatment from both clinician and patients\u2019 perspectives. J Clin Urol 11:339\u2013344","journal-title":"J Clin Urol"},{"key":"7664_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12325-019-01205-z","volume":"37","author":"S De Wachter","year":"2020","unstructured":"De Wachter S, Knowles CH, Elterman DS et al (2020) New technologies and applications in sacral neuromodulation: an update. Adv Ther 37:637\u2013643","journal-title":"Adv Ther"},{"issue":"Supplement 1","key":"7664_CR26","first-page":"S178","volume":"85","author":"MA PerrouinVerbe","year":"2024","unstructured":"PerrouinVerbe MA, Goudelocke C, Xavier K et al (2024) Device programming, MRI utilization and safety of sacral neuromodulation through 24 months in a global post-market study. Eur Urol 85(Supplement 1):S178","journal-title":"Eur Urol"},{"key":"7664_CR27","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s00330-019-06449-5","volume":"30","author":"AN Bhuva","year":"2020","unstructured":"Bhuva AN, Moralee R, Moon JC et al (2020) Making MRI available for patients with cardiac implantable electronic devices: growing need and barriers to change. Eur Radiol 30:1378\u20131384","journal-title":"Eur Radiol"},{"key":"7664_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001598","volume":"8","author":"C Pieri","year":"2021","unstructured":"Pieri C, Bhuva A, Moralee R et al (2021) Access to MRI for patients with cardiac pacemakers and implantable cardioverter defibrillators. Open Heart 8:e001598","journal-title":"Open Heart"},{"key":"7664_CR29","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1161\/CIRCULATIONAHA.105.607655","volume":"114","author":"S Nazarian","year":"2006","unstructured":"Nazarian S, Roguin A, Zviman MM et al (2006) Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 Tesla. Circulation 114:1277\u20131284","journal-title":"Circulation"},{"key":"7664_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/jmri.24971","volume":"43","author":"S Nazarian","year":"2016","unstructured":"Nazarian S, Reynolds MR, Ryan MP et al (2016) Utilization and likelihood of radiologic diagnostic imaging in patients with implantable cardiac defibrillators. J Magn Reson Imaging 43:115\u2013127","journal-title":"J Magn Reson Imaging"},{"key":"7664_CR31","first-page":"425","volume":"19","author":"K Sabzevari","year":"2017","unstructured":"Sabzevari K, Oldman J, Herrey AS et al (2017) Provision of magnetic resonance imaging for patients with \u2019MR-conditional\u2019 cardiac implantable electronic devices: an unmet clinical need. Europace 19:425\u2013431","journal-title":"Europace"},{"key":"7664_CR32","unstructured":"https:\/\/uroweb.org\/news\/22-stakeholders-sign-manifesto-for-policy-reform-on-continence-health-in-europe"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07664-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-024-07664-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07664-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T08:25:41Z","timestamp":1726129541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-024-07664-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["7664"],"URL":"https:\/\/doi.org\/10.1007\/s00404-024-07664-2","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}